Scisparc Ltd. annual report, Q4 FY2019

Business context and reporting period

The supplied filing is Therapix Biosciences Ltd.’s Form 20-F for the fiscal year ended December 31, 2019, filed June 15, 2020. It reports annual results, not standalone 2019 fourth-quarter results. The request identifies Scisparc Ltd.; the filing itself names Therapix Biosciences Ltd. Financial statements are audited and prepared under IFRS, in U.S. dollars; amounts below are in millions unless stated otherwise.

Therapix was a clinical-stage pharmaceutical company developing cannabinoid-based candidates: THX-110 for Tourette syndrome and obstructive sleep apnea (OSA), THX-160 for pain, and THX-210 for autism spectrum disorder and epilepsy. It had no product sales or operating revenue.

Financial performance and position

The company reported negative working capital of approximately $0.091 million, an accumulated deficit of $51.706 million, and a going-concern warning from its auditor. It said it needed substantial additional capital and that funding available at the financial-statement approval date was not sufficient for the foreseeable future. At December 31, 2019, convertible debentures were fully converted or otherwise settled; current liabilities included $0.067 million of credit from others, and lease liabilities totaled $0.094 million. No gross margin is meaningful because there was no revenue.

Changes versus the prior comparable period

Net loss narrowed by about 48%, and operating loss by about 43%, primarily because research and development and administrative spending fell. R&D expense declined 39%, partly because no new clinical studies were initiated during 2019; G&A expense declined 44%, including lower business-development, payroll, and investor-relations costs. These reductions reflect lower spending, not revenue growth. Net finance expense increased to $0.371 million from net finance income of $0.707 million in 2018, mainly due to debenture-related expenses and warrant issuance costs.

Operating cash outflow improved to $4.696 million from $7.132 million. Investing activities provided $1.268 million, principally from equipment sales and repayment of a convertible loan; financing activities provided $2.804 million, including share and warrant proceeds. Ordinary shares outstanding increased to 228,788,014 at year-end from 140,252,374 a year earlier. The company recorded $0.207 million of loss from discontinued operations in 2019; Therapix Healthcare Resources (THR), which operated pain clinics, was liquidated and deconsolidated during the year.

Outlook, developments, and material risks

• Clinical programs: The company reported positive topline Phase IIa OSA results in November 2019: nine of ten enrolled patients completed the study, and the filing reports an approximately 54% average reduction in apnea-hypopnea index among completers; one patient withdrew due to dizziness. The small, open-label study does not establish efficacy. A separate 16-person, open-label Tourette study reported a 21% average reduction in tic scores; the company was preparing a German regulatory dossier and described plans for a controlled study. THX-210 was advanced toward clinical development after in-vitro synergy results. THX-160 remained preclinical.
• Funding and dilution: The company stated it expected no meaningful product revenue for the next few years and would rely on debt or equity financing. It reported cash and short-term deposits of $0.880 million at year-end and $0.299 million as of June 9, 2020, after subsequent financing activity. The April 2020 offering generated approximately $1.2 million to $1.25 million gross, according to different sections of the filing, and involved pre-funded and Series B warrants. A March 2020 convertible-note placement with the Executive Chairman also carried potential dilution. The company said it could not assure further financing on acceptable terms.
• Going concern and operations: The auditor’s report states substantial doubt exists about the company’s ability to continue as a going concern; the financial statements contain no adjustments that might result if it cannot continue. Lack of funding had led to employee reductions, and the company warned additional cuts might be required. COVID-19 disrupted operations, could delay trials and recruitment, and contributed to the late filing; management said the full impact was uncertain.
• Listing and governance: Nasdaq had notified the company of noncompliance with its stockholders’ equity requirement. After subsequent transactions, management believed it had regained compliance but said this was not assured; it also faced a $1 bid-price requirement with a stated November 5, 2020 compliance deadline. A major shareholder demanded a meeting to replace the board, creating proxy-contest and cash-use risk.
• Licenses and contingencies: As of June 14, 2020, the company said it had not paid Yissum’s $133,000 initial license payment, placing the THX-160 license in breach and exposing it to possible termination. A $75,000 milestone payable under the related-party Dekel license was recorded at year-end and paid in April 2020. A former service provider asserted an approximately $85,000 claim, which management disputed and did not provide for. The filing says no material legal proceedings were pending.
• Subsequent strategic transaction: In May 2020, the company transferred its THX-110 sleep technology to subsidiary Evero and received a 35% interest in private Coeruleus through the transaction. The value and liquidity of that private-company investment are uncertain. The filing also states the company did not expect to complete the proposed Heavenly Rx business combination.

Important facts for investors to verify

1. Confirm the issuer identity and reporting period: this source is Therapix Biosciences Ltd.’s FY 2019 Form 20-F, not a standalone Q4 report; reconcile it to the Scisparc Ltd. request.
2. Review the audited financial statements and going-concern disclosure, and verify current cash, burn rate, working capital, and funding runway beyond the filing’s June 2020 snapshot.
3. Reconcile the April 2020 offering’s gross-proceeds figures ($1.2 million versus approximately $1.25 million) and assess subsequent warrant exercises, conversions, and dilution.
4. Check the status of Nasdaq equity and bid-price compliance and the outcome of the requested shareholder meeting or any proxy contest.
5. Verify whether the Yissum license breach was cured and whether the THX-160 rights remain in force; also review related-party terms and the Dekel milestone payment.
6. Assess the full study reports, safety data, and regulatory path for THX-110 and THX-210; the reported early-stage results are not proof of clinical benefit or approval prospects.